MAPT and Alzheimer disease: Lastly, pharmacological activation of CYP46A1 by the HIV-drug efavirenz reduces phosphorylated Tau levels in human induced pluripotent stem cell-derived neurons (45) and low-dose efavirenz is currently being investigated as a strategic therapy to reduce Tau pathology in AD (46, 47).